Great question, Saul. Like you said, it is still early, and we don’t yet have robust, long-term data linking organoid preclinical testing to improved clinical success rates.
That said, there’s promising evidence, especially in oncology. Several studies have shown that patient-derived organoids can predict individual responses to chemotherapy with 80–90% accuracy in colorectal cancer, for example. But I think translating that into higher drug approval rates or broader clinical outcomes will take time.
I’d guess we’re at least 5 to10 years away from having enough hybrid preclinical/clinical data to really quantify their impact on success rates in a meaningful way.
Fascinating concept, using these human driven organoids might be more accurate for testing purposes than on animals.
I’m wondering if there is any data on clinical success rates based on the use of organoids at the pre-clinical stage? Too early perhaps?
Great question, Saul. Like you said, it is still early, and we don’t yet have robust, long-term data linking organoid preclinical testing to improved clinical success rates.
That said, there’s promising evidence, especially in oncology. Several studies have shown that patient-derived organoids can predict individual responses to chemotherapy with 80–90% accuracy in colorectal cancer, for example. But I think translating that into higher drug approval rates or broader clinical outcomes will take time.
I’d guess we’re at least 5 to10 years away from having enough hybrid preclinical/clinical data to really quantify their impact on success rates in a meaningful way.
I would be interested to know if using non-animal approaches might actually improve our understanding of human biology and the pathology of diseases?